Entering text into the input field will update the search result below

Provention Bio pauses enrollment in PRV-031 study due to COVID-19

Mar. 16, 2020 9:53 PM ETProvention Bio, Inc. (PRVB) StockPRVBBy: Douglas W. House, SA News Editor4 Comments
  • Citing the need for caution during the COVID-19 outbreak, Provention Bio (NASDAQ:PRVB) has suspended recruitment in its Phase 3 PROTECT study evaluating teplizumab (PRV-031) in newly diagnosed type 1 diabetics.
  • Currently enrolled patients will be allowed to complete treatment.
  • There are no safety or efficacy issues involved.
  • The company says it remains on track to file its U.S. marketing application in Q4.

Recommended For You

Related Stocks

SymbolLast Price% Chg
PRVB--
Provention Bio, Inc.